AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2017, Avadel Pharmaceuticals plc (the Company) issued a
press release announcing its earnings for the quarter ended March
31, 2017. That press release is attached as Exhibit 99.1 and is
incorporated herein by reference.
press release announcing its earnings for the quarter ended March
31, 2017. That press release is attached as Exhibit 99.1 and is
incorporated herein by reference.
The information responsive to this Item 2.02 of this Form 8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 (the Securities Act) or the Exchange
Act, except as may be expressly set forth by specific reference
in such a filing.
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 (the Securities Act) or the Exchange
Act, except as may be expressly set forth by specific reference
in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
99.1
|
Press release dated May 9, 2017, issued by Avadel
Pharmaceuticals plc * |
|
* This information shall be deemed to be “furnished” and not
filed herewith.
filed herewith.
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Recent Trading Information
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) closed its last trading session down -0.09 at 9.10 with 177,945 shares trading hands.
